Skip to main content
← All trials
Adverse Reaction to VaccineDigital healthBiological

What this study is

This project aims to monitor the side effects of COVID-19 vaccines worldwide actively. The primary objectives of the project include a) to estimate the prevalence of each local and systemic side effect of each COVID-19 vaccine among healthcare workers (HCW), old adults over +65 (OA), and schoolteachers (ST); b) to evaluate the potential demographic and medical risk factors for side effects frequency and intensity; c) to evaluate the long-term consequences of COVID-19 vaccines. The secondary objectives include a) to evaluate the relative safety of COVID-19 vaccines compared to each other; b) to evaluate the impact of palliative drugs used by the recently vaccinated individuals on their short-term side effects resolution.

What's being tested

  • BNT162b2

    Intervention · BIOLOGICAL

    Receiving either the first dose only or both doses of BNT162b2 vaccine (Pfizer-BioNTech COVID-19 Vaccine)

  • mRNA-1273

    Intervention · BIOLOGICAL

    Receiving either the first dose only or both doses of mRNA-1273 vaccine (Moderna COVID-19 Vaccine)

  • AZD1222

    Intervention · BIOLOGICAL

    Receiving either the first dose only or both doses of AZD1222 vaccine (AstraZeneca-Oxford University COVID-19 Vaccine)

  • CoronaVac

    Intervention · BIOLOGICAL

    Receiving either the first dose only or both doses of CoronaVac (Sinovac COVID-19 Vaccine)

  • Sinopharm

    Intervention · BIOLOGICAL

    Receiving either the first dose only or both doses of Sinopharm Vero Cell COVID-19 Vaccine

  • Gam-COVID-Vac

    Intervention · BIOLOGICAL

    Receiving either the first dose only or both doses of Gam-COVID-Vac (Sputnik V)

  • JNJ-78436735

    Intervention · BIOLOGICAL

    Receiving JNJ-78436735 (Janssen COVID-19 Vaccine)

  • CVnCoV

    Intervention · BIOLOGICAL

    Receiving either the first dose only or both doses of CVnCoV (CureVac COVID-19 vaccine)

  • NVX-CoV2373

    Intervention · BIOLOGICAL

    Receiving either the first dose only or both doses of NVX-CoV2373 (Novavax COVID-19 vaccine)

  • BBV152

    Intervention · BIOLOGICAL

    Receiving either the first dose only or both doses of BBV152 (Covaxin COVID-19 vaccine)

Study details

Official title
COVID-19 Vaccines Safety Tracking: Global Consortium Study
Sponsor
Masaryk University
Conditions
Adverse Reaction to Vaccine · COVID19 Vaccine
Enrolling
30,000 people
Starts
2021-04-01
Est. completion
2026-12-31
Record
View on ClinicalTrials.gov ↗